## **Supporting Information**

## Pain Chemogenomics Knowledgebase (Pain-CKB) for Systems Pharmacology Target Mapping and PBPK Modeling Investigation of Opioid Drug-Drug Interactions

Mingzhe Shen<sup>1,#</sup>, Maozi Chen<sup>1,#</sup>, Tianjian Liang<sup>1</sup>, Siyi Wang<sup>1</sup>, Ying Xue<sup>2</sup>,

## Richard Bertz<sup>1,\*</sup>,Xiang-Qun Xie<sup>1,\*</sup>, Zhiwei Feng<sup>1,\*</sup>

<sup>1</sup>Department of Pharmaceutical Sciences and Computational Chemical Genomics Screening Center, School of Pharmacy; National Center of Excellence for Computational Drug Abuse Research; Drug Discovery Institute; Departments of Computational Biology and Structural Biology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, United States

<sup>2</sup>Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA



**Figure S1. Observed and simulated concentration–time profiles of acetaminophen 650 mg iv infusion over 5 min.** The simulated results were generated using 10 trials of 10 virtual healthy volunteers. Observed data<sup>1</sup> were highlighted in red dots while the simulated results, mean value, and the 95th/5th percentile of the simulation were shown by corresponding lines.



**Figure S2. Observed and simulated concentration-time profiles of acetaminophen 1000 mg iv infusion over 15 min.** The simulated results were generated using 10 trials of 10 virtual healthy Japanese volunteers. Observed data<sup>2</sup> were highlighted in red dots while the simulated results, mean value, and the 95th/5th percentile of the simulation were shown by corresponding lines.



Figure S3. Observed and simulated concentration-time profiles of fentanyl 100  $\mu$ g/kg iv bolus. The simulated results were generated using 10 trials of 10 virtual healthy volunteers. Observed data<sup>3</sup> were highlighted in red dots while the simulated results, mean value, and the 95th/5th percentile of the simulation were shown by corresponding lines.



Figure S4. Observed and simulated concentration-time profiles of fentanyl 5  $\mu$ g/kg iv bolus. The simulated results were generated using 10 trials of 10 virtual healthy volunteers. Observed data<sup>4</sup> were highlighted in red dots while the simulated results, mean value, and the 95th/5th percentile of the simulation were shown by corresponding lines.



Figure S5. The AUC Ratio of fentanyl with acetaminophen when Ki value is ranged in 2800-3200  $\mu$ M. The dosage of fentanyl and acetaminophen (inhibition substrate) is 0.003 mg/kg and 80000 mg.



Figure S6. Computational systems pharmacology-target mapping (CSP-Target Mapping) for NAPQI. The purple dots and dashed lines represent the predicted targets and interaction. Our algorithm predicted NAPQI may bind to TrxR.

## References

1. Scavone, J. M., Greenblatt, D. J., Blyden, G. T., Luna, B. G., and Harmatz, J. S. (1990) Validity of a Two-Point Acetaminophen Pharmacokinetic Study, *Ther. Drug Monit.* 12, 35-39.

2. Imaizumi, T., Obara, S., Mogami, M., Iseki, Y., Hasegawa, M., and Murakawa, M. (2017) Population pharmacokinetics of intravenous acetaminophen in Japanese patients undergoing elective surgery, *J. Anesth.* 31, 1-9.

3. Brusset, A., Levron, D. J. C., Olivier, P., Schlumberger, S., Moing, J. P. L., Dubois, C., Guilmet, D., Valide, L., Guenoun, T., and Fischler, M. (1999) Comparative Pharmacokinetic Study of Fentanyl and Sufentanil after Single High-Bolus Doses, *Clin. Drug Invest.* 18, 377-389.

4. Saari, T. I., Laine, K., Neuvonen, M., Neuvonen, P. J., and Olkkola, K. T. (2008) Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl, *Eur. J. Clin. Pharmacol.* 64, 25-30.